NCT05754047View on ClinicalTrials.gov

Tumor Characteristics and Survival Rate of HER2-Low Breast Cancer Patients

CompletedOBSERVATIONAL
Enrollment

3,582

Participants

Timeline

Start Date

April 30, 1991

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2022

Conditions
HER2 Low Breast Carcinoma
Interventions
DIAGNOSTIC_TEST

immunohistochemistry (IHC) and in situ hybridization (ISH) Test

These tests are usually applied for breast cancer patients to assist the surgeon to better understand the clinicopathological characteristics and survival features of tumors

All Listed Sponsors
lead

Mahdis Bayat

OTHER

NCT05754047 - Tumor Characteristics and Survival Rate of HER2-Low Breast Cancer Patients | Biotech Hunter | Biotech Hunter